Plethora Solutions Holdings plc is is a specialty pharmaceutical company engaged in the development and sale of drugs and medical devices for the diagnosis, treatment and management of urology, sexual health, gynecology and reproductive health conditions. The Company operates in two segments: Plethora Development and The Urology Co. The Plethora Development segment is engaged in the development of new pharmaceutical products. The Urology Co is the Company�s specialty sales and marketing business engaged in the sale and marketing of pharmaceutical and healthcare products in the United Kingdom and continental Europe. The Company�s product portfolio consists of its generic pharmaceutical products and over the counter (OTC) products. Its PSD502 is a treatment for premature ejaculation, sometimes referred to as (PE). As of December 31, 2011, the Company�s subsidiaries include Plethora Solutions Limited, The Urology Company Holdings Limited and The Urology Company Limited.